# Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)

> **NCT07717580** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 46 (estimated)

## Conditions studied

- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Primary Cutaneous Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin (Bv)
- **DRUG:** Lisaftoclax (APG-2575)

## Key facts

- **NCT ID:** NCT07717580
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2028-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717580, "Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07717580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*